Biologics

Thomson Reuters Introduces Biologics Module to its Newport Premium Solution

Published in Drug Law Weekly, April 5th, 2011

2011 APR 5 -- Add-on Module Provides Intelligence on Biologic and Biosimilar Drugs

Philadelphia, PA, London, UK, - Thomson Reuters announced the launch of the Newport Biologics Module, the most essential source of competitive intelligence for the rapidly growing market in biologic and biosimilar drugs.

The development of biological drugs has seen a dramatic increase during the past five years with nearly 6,000 clinical trials with a biological intervention being reported since 2005, according to Thomson Reuters. With this increase have come new government regulations promoting competition in the sector.

The Newport...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Drug Law Weekly

Source: Drug Law Weekly (2011-04-05)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry